Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy

Alter H.J. , Purcell R.H. , Shih J.W. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494–1500.

Cooper S. , Erickson A.L. , Adams E.J. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439–449.

Lee S.H. , Kim Y.K. , Kim C.S. E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005; 175: 8226–8235.

Akuta N. , Chayama K. , Suzuki F. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 allele. J Med Virol 2001; 64: 109–116.

Dusheiko G.M. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepat 1998; 5 Suppl 1: 9–12.

Ikeda K. , Saitoh S. , Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930–938.

Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–1233.

Niederau C. , Lange S. , Heintges T. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687–1695.

Davis G.L. , Balart L.A. , Schiff E.R. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–1506.

Di Bisceglie A.M. , Martin P. , Kassianides C. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–1510.

Davis G.L. , Esteban-Mur R. , Rustgi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–1499.

McHutchison J.G. , Gordon S.C. , Schiff E.R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.

Reichard O. , Norkrans G. , Fryden A. , Braconier J.H. , Sonnerborg A. , Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83–87.

Schalm S.W. , Hansen B.E. , Chemello L. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961–966.

Fried M.W. , Shiffman M.L. , Reddy K.R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

Hoofnagle J.H. , Ghany M.G. , Kleiner D.E. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66–74.

Manns M.P. , McHutchison J.G. , Gordon S.C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

Akuta N. , Suzuki F. , Kawamura Y. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686–1695.

Akuta N. , Suzuki F. , Kawamura Y. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403–410.

Conjeevaram H.S. , Fried M.W. , Jeffers L.J. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470–477.

Hiramatsu N. , Oze T. , Tsuda N. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006; 35: 185–189.

Sezaki H. , Suzuki F. , Kawamura Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009 54: 1317–1324.

Hiramatsu N. , Kurashige N. , Oze T. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res 2008; 38: 52–59.

Abbate I. , Lo Iacono O. , Di Stefano R. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004; 40: 831–836.

Yen Y.H. , Hung C.H. , Hu T.H. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27: 72–79.

Akuta N. , Suzuki F. , Hirakawa M. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452–458.

Akuta N. , Suzuki F. , Kawamura Y. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50: 361–368.

Okanoue T. , Itoh Y. , Hashimoto H. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44: 952–963.

Mori N. , Imamura M. , Kawakami Y. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81: 640–649.

Kumada H. , Okanoue T. , Onji M. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8–13.

Loguercio C. , Di Pierro M. , Di Marino M.P. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35: 296–301.

Akuta N. , Suzuki F. , Sezaki H. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83–90.

Akuta N. , Suzuki F. , Sezaki H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372–380.

Kato N. , Hijikata M. , Ootsuyama Y. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 9524–9528.

Hadziyannis S.J. , Sette H. Jr. , Morgan T.R. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.

Enomoto N. , Sakuma I. , Asahina Y. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77–81.

Chayama K. , Tsubota A. , Kobayashi M. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745–749.

Kurosaki M. , Enomoto N. , Murakami T. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750–753.

Nagayama K. , Enomoto N. , Izumi N. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 2001; 48: 830–835.

Watanabe H. , Enomoto N. , Nagayama K. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001; 183: 1195–1203.

Hiraga N. , Imamura M. , Tsuge M. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007; 581: 1983–1987.

Kimura T. , Imamura M. , Hiraga N. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 2008; 89: 2108–2113.

Alexander W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002; 2: 410–416.

Auernhammer C.J. , Bousquet C. , Chesnokova V. , Melmed S. SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling. Ann N Y Acad Sci 2000; 917: 658–664.

Fujimoto M. , Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003; 24: 659–666.

Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778–809.

Sen G.C. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255–281.

Song M.M. , Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 1998; 273: 35056–35062.

Stoiber D. , Kovarik P. , Cohney S. , Johnston J.A. , Steinlein P. , Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol 1999; 163: 2640–2647.

Vlotides G. , Sorensen A.S. , Kopp F. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 2004; 320: 1007–1014.

Bode J.G. , Ludwig S. , Ehrhardt C. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488–490.

Gale M. Jr. , Blakely C.M. , Kwieciszewski B. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208–5218.

Polyak S.J. , Khabar K.S. , Paschal D.M. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75: 6095–6106.

Polyak S.J. , Khabar K.S. , Rezeiq M. , Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001; 75: 6209–6211.

Taguchi T. , Nagano-Fujii M. , Akutsu M. Hepatitis C virus NS5A protein interacts with 2’,5’-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol 2004; 85: 959–969.